<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Magnesium sulfate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Magnesium sulfate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Magnesium sulfate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9585" href="/d/html/9585.html" rel="external">see "Magnesium sulfate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11219" href="/d/html/11219.html" rel="external">see "Magnesium sulfate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20452590"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Epsom Salt [OTC];</li>
<li>GoodSense Epsom Salt [OTC];</li>
<li>M2 Magnesium [OTC];</li>
<li>Magnacaps [OTC] [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1023184"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Oral</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Parenteral</span>;</li>
<li>
<span class="list-set-name">Magnesium Salt</span></li></ul></div>
<div class="block don drugH1Div" id="F53462500"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> 1,000 mg of magnesium sulfate = 98.6 mg <b>elemental</b> magnesium = 8.12 mEq <b>elemental </b>magnesium = 4.06 mmol <b>elemental </b>magnesium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adequate intake (AI):</b> Dose expressed as <b>elemental</b>
<b>magnesium</b>: Oral: 30 mg daily; requirements may vary based on prematurity, postnatal age, and other clinical factors; serum magnesium concentrations should be monitored closely to determine patient-specific needs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-IOM.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-IOM.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17f3d8ea-e8de-4fac-bdfb-5dade41876cd">Hypomagnesemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypomagnesemia: Note:</b> Dose depends on clinical condition and serum magnesium concentration; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General dosing: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Dose expressed as <b>magnesium sulfate:</b> IM, IV: 25 to 50 mg/kg/dose every 8 to 12 hours for 2 to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dose expressed as <b>elemental magnesium:</b> IM, IV: 2.5 to 5 mg/kg/dose every 8 to 12 hours for 2 to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe (&lt;1.6 mg/dL or in presence of seizure due to neonatal hypocalcemia):</i> Dose expressed as <b>magnesium sulfate</b>: IV: 50 mg/kg/dose over 1 to 2 hours; may repeat dose in 12 hours if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49f9f738-6af6-4f95-9a2d-632309e0274b">Parenteral nutrition, maintenance magnesium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance magnesium requirement:</b> Dose expressed as <b>elemental magnesium:</b> IV: 0.3 to 0.5 <b>mEq/kg</b>/day as an additive to parenteral nutrition solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="615652a0-e63c-4893-b80b-2418b48a36b4">Torsades de pointes, ventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Torsades de pointes, ventricular tachycardia:</b> Dose expressed as <b>magnesium sulfate</b>: IV, Intraosseous: 25 to 50 mg/kg/dose; if pulseless, administer as a bolus; if pulse, administer over 10 to 20 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F191093"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>1,000 mg of magnesium sulfate = 98.6 mg <b>elemental</b> magnesium = 8.12 mEq <b>elemental</b> magnesium = 4.06 mmol <b>elemental </b>magnesium.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations</b>: Serum magnesium is poor reflection of repletion status as the majority of magnesium is intracellular; serum concentrations may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum concentrations in patients with normal renal function for most efficient repletion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17f3d8ea-e8de-4fac-bdfb-5dade41876cd">Hypomagnesemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypomagnesemia:</b> Infants, Children, and Adolescents: <b>Note:</b> Dose depends on clinical condition and serum magnesium concentration.</p>
<p style="text-indent:-2em;margin-left:4em;">Dose expressed as <b>magnesium sulfate:</b> IV, Intraosseous: 25 to 50 mg /kg/dose every 6 hours for 2 to 3 doses, then recheck serum concentration; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Kliegman.1','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Kliegman.1','lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dose expressed as <b>elemental magnesium:</b> IV: 2.5 to 5 mg/kg/dose every 6 hours for 2 to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="387e55f0-7a7e-4f50-ab02-5492aebb64f2">Constipation, occasional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation, occasional:</b>
<b>Note</b>: With OTC use, should not exceed recommended treatment duration (7 days) unless directed by health care provider.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: Oral: 1 to 2 level teaspoons of granules dissolved in 8 ounces of water; may repeat in 4 hours. Do not exceed 2 doses per day.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 2 to 4 level teaspoons of granules dissolved in 8 ounces of water; may repeat in 4 hours. Do not exceed 2 doses per day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49f9f738-6af6-4f95-9a2d-632309e0274b">Parenteral nutrition, maintenance magnesium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance magnesium requirement</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>): Dose expressed as <b>elemental</b>
<b>magnesium</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤50 kg: IV: 0.3 to 0.5 <b>mEq/kg</b>/day as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;50 kg and Adolescents: IV: 10 to 30 <b>mEq/</b>day as an additive to parenteral nutrition solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6de248b-a443-4bfe-8984-4660a1a15db7">Torsade de pointes or ventricular fibrillation/pulseless ventricular tachycardia associated with torsade de pointes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Torsade de pointes or ventricular fibrillation/pulseless ventricular tachycardia associated with torsade de pointes:</b> Dose expressed as <b>magnesium sulfate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, Intraosseous: 25 to 50 mg/kg/dose; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1ae6156-f37c-4148-9d98-cc4c884af25c">Asthma, acute refractory exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute refractory exacerbation:</b> Limited data available: Dose expressed as <b>magnesium sulfate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants, Children, and Adolescents: 50 mg/kg/dose as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30259065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30259065'])">Ref</a></span>); usual dose range: 25 to 75 mg/kg/dose; maximum dose: 2,000 mg/dose; recommended as adjunctive therapy in severe acute asthma for patients who have life-threatening exacerbations and in those whose exacerbations remain in the severe category after 1 hour of intensive conventional therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-GINA.2020','lexi-content-ref-17983880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-GINA.2020','lexi-content-ref-17983880'])">Ref</a></span>). Efficacy results have been variable in trials; some have shown significant improvement with single doses of 25 mg/kg/dose and 40 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8969721','lexi-content-ref-11030848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8969721','lexi-content-ref-11030848'])">Ref</a></span>) while others found no statistically significant difference compared to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11097697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11097697'])">Ref</a></span>). A pharmacokinetic modeling study of pediatric severe asthma suggested doses between 50 and 75 mg/kg to achieve concentrations within the hypothesized target range between 25 and 40 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27909740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27909740'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation: Severe exacerbation: Limited data available: Children ≥2 years and Adolescents: Nebulized 150 mg isotonic magnesium sulfate mixed with albuterol and ipratropium every 20 minutes for 3 doses in the first hour of treatment to patients with severe acute asthma who did not respond to standard inhalation treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2020','lexi-content-ref-24429155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2020','lexi-content-ref-24429155'])">Ref</a></span>). In a large randomized, placebo-controlled trial (n=508, including 252 who received magnesium sulfate treatment; ages: 2 to 16 years) improvement was statistically significant, but clinically significant changes were only observed in the most severe patients (SaO2 &lt;92% with symptoms lasting &lt;6 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24429155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24429155'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51129175"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<i>Hypomagnesemia: </i>There are no dosage adjustments provided in the manufacturer's labeling; use with caution; monitor closely for hypermagnesemia.</p></div>
<div class="block dohp drugH1Div" id="F51129176"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doa drugH1Div" id="F191085"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9585" href="/d/html/9585.html" rel="external">see "Magnesium sulfate: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>All doses in this monograph are expressed as magnesium sulfate salt unless stated otherwise. One gram of magnesium sulfate salt = 98.6 mg of elemental magnesium = 8.12 mEq of elemental magnesium = 4.06 mmol of elemental magnesium.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Serum magnesium levels do not correlate well with total body stores as the majority of magnesium is intracellular; serum concentrations may be transiently elevated for a few hours after administration of an IV dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9652168b-ca0c-4c2d-86a3-664ccf450509">Asthma, severe acute exacerbations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, severe acute exacerbations (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For severe or life-threatening exacerbations nonresponsive to initial therapy. Not recommended for routine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g as a single dose over 20 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="44e4c03e-fff2-449a-94aa-a8c1c6e9b8b1">Chronic obstructive pulmonary disease, severe acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, severe acute exacerbation (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For severe or life-threatening exacerbations nonresponsive to initial therapy. Not recommended for routine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099052','lexi-content-ref-35616126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099052','lexi-content-ref-35616126'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g as a single dose over 20 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099052','lexi-content-ref-26905985','lexi-content-ref-35616126','lexi-content-ref-7864705','lexi-content-ref-32542879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099052','lexi-content-ref-26905985','lexi-content-ref-35616126','lexi-content-ref-7864705','lexi-content-ref-32542879'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5cf5683d-351d-423d-a054-afa1e6798e5c">Constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For occasional use only. Use in some patients (eg, in those with cardiac dysfunction, kidney disease) may result in electrolyte disturbances and volume overload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14523145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14523145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC labeling (patient-guided therapy): </i>
<b>Oral:</b> 2 to 4 level teaspoons (~10 to 20 g) of granules dissolved in 8 ounces (240 mL) of water; may repeat in 4 hours. Do not exceed 2 doses per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19621856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19621856'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7d59fca1-38bc-4f42-8053-4d477325c970">Eclampsia/preeclampsia with severe features, seizure prophylaxis and treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eclampsia/preeclampsia with severe features, seizure prophylaxis and treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An optimal regimen has not been identified. Close monitoring (including kidney function [eg, urine output], respiration, and patellar reflexes) is required; monitoring of magnesium levels is recommended for patients with kidney impairment and in patients with signs of toxicity or seizure(s). Adjust dose to avoid maternal toxicity. Calcium gluconate should be available for treating severe magnesium toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-26629718','lexi-content-ref-20687086','lexi-content-ref-27885772','lexi-content-ref-26485229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-26629718','lexi-content-ref-20687086','lexi-content-ref-27885772','lexi-content-ref-26485229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 4 to 6 g loading dose over 15 to 30 minutes at onset of labor or induction/cesarean delivery, followed by 1 to 2 g/hour continuous infusion for at least 24 hours after delivery; maximum infusion rate: 3 g/hour. If seizure occurs while receiving magnesium, an additional bolus of 2 to 4 g may be administered over ≥5 minutes with frequent monitoring for toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-7769899','lexi-content-ref-16085929','lexi-content-ref-Norwitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-7769899','lexi-content-ref-16085929','lexi-content-ref-Norwitz.1'])">Ref</a></span>). Product labeling recommends a maximum dose of 40 g per 24 hours; however, this varies among regimens and institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM</b> (50% concentration): Initial: 10 g loading dose administered as 5 g in each buttock at onset of labor or induction/cesarean delivery, followed by 5 g every 4 hours for at least 24 hours after delivery. <b>Note:</b> Use IM route when unable to establish venous access (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-12057549','lexi-content-ref-Norwitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-12057549','lexi-content-ref-Norwitz.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c60f5dcd-0cf8-4ce4-be2a-7b6d1b2552d4">Fetal neuroprotection for imminent preterm birth</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fetal neuroprotection for imminent preterm birth (maternal administration) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An optimal regimen has not been identified. Close monitoring (including kidney function [eg, urine output], respiration, and patellar reflexes) is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simhan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simhan.1'])">Ref</a></span>). Generally used for pregnancies &lt;32 weeks' gestation with expected delivery within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27661654','lexi-content-ref-14645308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27661654','lexi-content-ref-14645308'])">Ref</a></span>). Regimens vary; consult institutional protocols. An example regimen is listed below:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 4 g loading dose over 20 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14645308','lexi-content-ref-17169012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14645308','lexi-content-ref-17169012'])">Ref</a></span>); may follow with a 1 g/hour continuous infusion for a maximum of 24 hours or until delivery, whichever comes first (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14645308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14645308'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30d03111-49d1-45b5-aa3b-9d812c4a0902">Hypomagnesemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypomagnesemia, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended dosing and infusion rates may vary among institutional protocols according to severity, clinical status (eg, if postoperative), and type of IV access (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Siparsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Siparsky.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Asymptomatic patients: </i>
<b>Note:</b> Oral replacement using a different salt (eg, magnesium chloride) is generally preferred if tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Yu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Yu.1'])">Ref</a></span>). Slow IV administration (≤1 g/hour) may provide more efficient repletion due to potential for rapid urinary elimination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>). Use IM only if IV access is unavailable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24100128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24100128'])">Ref</a></span>). Subsequent dosing may be based on daily serum magnesium concentrations; repletion may take several days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Mild deficiency (eg, serum magnesium &gt;1.5 to 1.9 mg/dL):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 1 to 2 g over 1 to 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Yu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Yu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IM</b> (50% concentration): 1 g every 6 hours for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24100128','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24100128','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate deficiency (eg, serum magnesium 1 to 1.5 mg/dL):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 2 to 4 g over 2 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-17686630','lexi-content-ref-19969151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-17686630','lexi-content-ref-19969151'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IM</b> (50% concentration): 1 g every 6 hours for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24100128','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24100128','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Severe deficiency (eg, serum magnesium &lt;1 mg/dL):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 4 to 8 g over 4 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23616673','lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23616673','lexi-content-ref-16085929'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptomatic patients (eg, tetany, arrhythmias, seizures) (excluding torsades de pointes and eclampsia/preeclampsia):</i>
<b>Note: </b>Continuous cardiac monitoring strongly recommended. Subsequent dosing may be based on serum magnesium levels assessed 6 to 12 hours after initial dosing. Repletion may take several days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Yu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Yu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b></p>
<p style="text-indent:-2em;margin-left:8em;">Hemodynamically unstable: Initial: 1 to 2 g administered as a bolus over 2 to 15 minutes; may repeat as needed if patient remains unstable; once patient is stable, administer an additional 4 to 8 g over 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Yu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Yu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodynamically stable: Initial: 1 to 2 g over 5 to 60 minutes, followed by an additional 4 to 8 g over 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-Yu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-Yu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f7203a-e10c-47ac-b028-3c148b2d3e81">Parenteral nutrition</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Parenteral nutrition ordering requires advanced knowledge of nutrient and other metabolic requirements and should only be prescribed by clinicians trained in assessment and order writing for parenteral nutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26078288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26078288'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Standard daily magnesium requirement<b>:</b></i>
<b>IV:</b> Elemental magnesium 8 to 20 mEq (4 to 10 mmol) daily as component of parenteral nutrition; adjust daily dose based on serum magnesium and clinical considerations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASPEN.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASPEN.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4cf251a-7084-4fc9-bd00-62e5911e9f5f">Torsades de pointes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Torsades de pointes (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Polymorphic ventricular tachycardia (with pulse) associated with QT prolongation (torsades de pointes):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 1 to 2 g (diluted in 50 to 100 mL D5W) over 15 minutes (range: 5 to 60 minutes). If no response or torsades de pointes recurs, may repeat dose up to a total of 4 g in 1 hour; may follow with a continuous IV infusion of 0.5 to 1 g/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hazinski.1','lexi-content-ref-20956224','lexi-content-ref-30571262','lexi-content-ref-Berul.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hazinski.1','lexi-content-ref-20956224','lexi-content-ref-30571262','lexi-content-ref-Berul.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Ventricular fibrillation/pulseless ventricular tachycardia associated with torsades de pointes:</i> Note: </b>Administer in conjunction with electrical cardioversion/defibrillation<b>. </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV/intraosseous:</b> 1 to 2 g (diluted in 10 mL D5W) administered as a bolus over ≥1 to 2 minutes; if ineffective, may repeat immediately (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-30571262','lexi-content-ref-Berul.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-30571262','lexi-content-ref-Berul.1'])">Ref</a></span>); use intraosseous route if IV not available. Some experts recommend a 2 g bolus initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pozner.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pozner.1'])">Ref</a></span>) and repeat up to 2 additional 2 g bolus doses as needed; maximum total dose: 6 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berul.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berul.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990457"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For indications that generally necessitate the use of ≤2 bolus doses (eg, treatment of asthma/chronic obstructive pulmonary disease exacerbations, torsades de pointes, symptomatic hypomagnesemia), no dosage adjustment is necessary for patients with kidney impairment or receiving kidney replacement therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>General recommendations:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: <b>IV, IM:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;30 mL/minute: <b>IV, IM: </b>Administer 50% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26069820','lexi-content-ref-16085929','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26069820','lexi-content-ref-16085929','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution; frequent monitoring for hypermagnesemia is required.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: <b>IV, IM: </b>Hypermagnesemia develops frequently in patients with CrCl &lt;10 mL/minute. If necessary, administer 50% of the usual indication-specific dose with extreme caution; frequent monitoring for hypermagnesemia is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26069820','lexi-content-ref-16085929','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26069820','lexi-content-ref-16085929','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Indication-specific recommendations: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Constipation: </b></p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥60 mL/minute:<b> Oral:</b> No dosage adjustment necessary; for occasional use only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to &lt;60 mL/minute:<b> Oral:</b> Consider alternative agent. If used, administer doses on the low end of the recommended range and limit to occasional use only (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Eclampsia/Preeclampsia with severe features, seizure prophylaxis and treatment: </b>An optimal regimen has not been identified; refer to institutional protocols. Close monitoring (including kidney function [eg, urine output], respiration, and patellar reflexes) is required; monitoring of magnesium levels is recommended for patients with preexisting or acute kidney impairment and in patients with signs of toxicity or seizure(s). Adjust dose to avoid maternal and fetal toxicity. Calcium gluconate should be available for treating severe magnesium toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Patients with acute kidney injury (significant rise in creatinine above baseline) or oliguria (&lt;30 mL/hour urine output for more than 4 hours) also may warrant dose reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥60 mL/minute:<b> IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to &lt;60 mL/minute: <b>IV: </b>Initial: 4 to 6 g loading dose over 15 to 30 minutes at onset of labor or induction/cesarean delivery, followed by 1 g/hour continuous infusion for at least 24 hours after delivery. <b>Note:</b> Monitor magnesium concentrations frequently (eg, at least every 4 hours) to avoid accumulation and adverse effects associated with hypermagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Norwitz.2','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Norwitz.2','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: <b>IV: </b>Initial: 4 to 6 g loading dose over 15 to 30 minutes at onset of labor or induction/cesarean delivery. Continuous maintenance infusion is not recommended due to risk of accumulation, but intermittent magnesium supplementation may be administered as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Norwitz.2','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Norwitz.2','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Use with extreme caution; monitor magnesium levels frequently (eg, at least every 2 to 4 hours) to inform the need for additional doses and avoid accumulation and adverse effects associated with hypermagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Norwitz.2','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Norwitz.2','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Per the manufacturer, do not exceed 20 g in patients with severe kidney impairment during a 48-hour period.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Fetal neuroprotection for imminent preterm birth (maternal administration) (off-label use): Note: </b>An optimal regimen has not been identified; refer to institutional protocols. Close monitoring (including kidney function [eg, urine output], respiration, and patellar reflexes) is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simhan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simhan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Patients with acute kidney injury (significant rise in creatinine above baseline) or oliguria (&lt;30 mL/hour urine output for more than 4 hours) also may warrant dose reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥60 mL/minute: <b>IV:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 30 to &lt;60 mL/minute: <b>IV:</b> Initial: 4 g loading dose over 20 to 30 minutes; may follow with a continuous infusion at 50% of usual infusion rate for a maximum of 24 hours or until delivery, whichever comes first. <b>Note:</b> Monitor magnesium levels frequently (eg, at least every 4 hours) to avoid accumulation and adverse effects associated with hypermagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simhan.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simhan.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: <b>IV: </b>Initial: 4 g loading dose over 20 to 30 minutes. Continuous maintenance infusion is not recommended due to risk of accumulation, but intermittent magnesium supplementation may be administered if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> Use with extreme caution; monitor magnesium levels frequently (eg, at least every 2 to 4 hours) to inform the need for additional doses and avoid accumulation and adverse effects associated with hypermagnesemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simhan.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simhan.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (extent unknown, removal will depend on magnesium concentration in dialysate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32498528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32498528'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">General recommendations: Dose as for patients with CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Indication-specific recommendations: Dose as for patients with CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">General recommendations: Dose as for patients with CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Indication-specific recommendations: Dose as for patients with CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b> Dose as for patients with CrCl 10 to &lt;30 mL/minute; consider magnesium concentration in dialysate and replacement fluids as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27391902','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27391902','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b> Dose as for patients with CrCl 10 to &lt;30 mL/minute; consider magnesium concentration in dialysate and replacements fluids as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27391902','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27391902','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987681"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F191057"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse effects on neuromuscular function may occur at lower concentrations in patients with neuromuscular disease (eg, myasthenia gravis).</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (IV; dose related), hypotension (IV; rate related), vasodilation (IV; rate related)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypermagnesemia</p></div>
<div class="block coi drugH1Div" id="F191073"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to any component of the formulation; heart block (see <b>Note</b>); myocardial damage; IV use for preeclampsia/eclampsia during the 2 hours prior to delivery (see <b>Note</b>)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> Although the manufacturers' labeling for some IV formulations state use in preeclampsia/eclampsia during the 2 hours prior to (cesarean) delivery is contraindicated due to interaction with neuromuscular-blocking agents intraoperatively; stopping magnesium sulfate prior to cesarean delivery in these patients is not recommended and increases the risk of seizure. Instead, magnesium should be continued prior to and during the delivery (ACOG 2013). Additionally, the manufacturers' labeling for some IV formulations contraindicate the use of magnesium sulfate in the setting of heart block; however, the use of magnesium is appropriate in patients with serious conditions requiring magnesium therapy who either have mild degrees of heart block (eg, first degree) or more severe forms of heart block with a temporary or permanent cardiac pacemaker.</p></div>
<div class="block war drugH1Div" id="F191054"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Obstetrics: Vigilant monitoring and safe administration techniques (ISMP 2005) are recommended to avoid potential for errors resulting in toxicity. Monitor mother and fetus closely. Use longer than 5 to 7 days may cause adverse fetal events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Unlikely to effectively terminate irregular/polymorphic VT (with normal baseline QT interval) (AHA [Neumar 2010]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte abnormalities: Concurrent hypokalemia or hypocalcemia can accompany a magnesium deficit. Hypomagnesemia is frequently associated with hypokalemia and requires correction in order to normalize potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral administration: Magnesium toxicity can lead to fatal cardiovascular arrest and/or respiratory paralysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used as a laxative, patients should consult a health care provider prior to use if they have: kidney disease; are on a magnesium-restricted diet; have abdominal pain, nausea, or vomiting; change in bowel habits lasting &gt;2 weeks; have already used a laxative for &gt;1 week.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878536"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or underdosing. </p></div>
<div class="block dosfc drugH1Div" id="F21963611"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">1 g of magnesium sulfate = 98.6 mg of elemental magnesium = 8.12 mEq of elemental magnesium = 4.06 mmol of elemental magnesium.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Magnesium sulfate 1% [10 mg/mL] in Dextrose 5% injection is equivalent to elemental magnesium 0.081 mEq/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium sulfate 2% [20 mg/mL] in Dextrose 5% injection is equivalent to elemental magnesium 0.162 mEq/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium sulfate 4% [40 mg/mL] in Water injection is equivalent to elemental magnesium 0.325 mEq/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium sulfate 8% [80 mg/mL] in Water injection is equivalent to elemental magnesium 0.65 mEq/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium sulfate 50% injection is equivalent to elemental magnesium 4 mEq/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium sulfate USP is supplied as magnesium sulfate heptahydrate</p></div>
<div class="block foc drugH1Div" id="F191066"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">M2 Magnesium: 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Magnacaps: 100 mg [DSC] [corn free, rye free, wheat free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Granules, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epsom Salt:  (454 g, 1810 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Epsom Salt:  (454 g, 1810 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50% (10 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50% (2 mL, 10 mL, 20 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g/100 mL (100 mL); 1 g/100 mL (100 mL); 2 g/50 mL (50 mL); 20 g/500 mL (500 mL); 4 g/50 mL (50 mL); 40 g/1000 mL (1000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g/100 mL (100 mL); 1 g/100 mL (100 mL); 2 g/50 mL (50 mL); 20 g/500 mL (500 mL); 4 g/50 mL (50 mL); 40 g/1000 mL (1000 mL)</p></div>
<div class="block geq drugH1Div" id="F191050"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323358"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Magnesium Sulfate in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM/100ML 5% (per mL): $0.04 - $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Magnesium Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50% (per mL): $0.72 - $1.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Magnesium Sulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 gm/50 mL (per mL): $0.11 - $0.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g/100 mL (per mL): $0.04 - $0.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 gm/50 mL (per mL): $0.10 - $0.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 g/500 mL (per mL): $0.01 - $0.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40GM/1000ML (per mL): $0.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867425"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20% (10 mL); 49.3% (500 mL); 50% (10 mL, 50 mL)</p></div>
<div class="block adip drugH1Div" id="F53567529"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">1,000 mg of magnesium sulfate = 98.6 mg <b>elemental</b> magnesium = 8.12 mEq <b>elemental</b> magnesium = 4.06 mmol <b>elemental</b> magnesium.</p>
<table border="1" data-table-id="magsupp" frame="border" rules="all">
<caption style="text-align:center;">
<b>Elemental Magnesium Content of Magnesium Salts</b></caption>
<colgroup><col/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Magnesium Salt</p></th>
<th align="center">
<p style="text-indent:0em;">Elemental Magnesium</p>
<p style="text-indent:0em;">(mg/1,000 mg salt)</p></th>
<th align="center">
<p style="text-indent:0em;">Magnesium</p>
<p style="text-indent:0em;">(mEq/1,000 mg salt)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td>
<p style="text-indent:0em;">Magnesium chloride</p></td>
<td align="center">
<p style="text-indent:0em;">119.7</p></td>
<td align="center">
<p style="text-indent:0em;">9.85</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Magnesium gluconate</p></td>
<td align="center">
<p style="text-indent:0em;">54</p></td>
<td align="center">
<p style="text-indent:0em;">4.44</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Magnesium L-aspartate</p></td>
<td align="center">
<p style="text-indent:0em;">99.18</p></td>
<td align="center">
<p style="text-indent:0em;">8.16</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Magnesium oxide</p></td>
<td align="center">
<p style="text-indent:0em;">603.25</p></td>
<td align="center">
<p style="text-indent:0em;">49.64</p></td></tr>
<tr>
<td>
<p style="text-indent:0em;">Magnesium sulfate</p></td>
<td align="center">
<p style="text-indent:0em;">98.6</p></td>
<td align="center">
<p style="text-indent:0em;">8.12</p></td></tr></tbody></table></div>
<div class="block admp drugH1Div" id="F52613218"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Must dissolve granules prior to administration. When used as a laxative, the patient should drink a full 8 ounces of liquid following each dose. Lemon juice may be added to the initial solution to improve the taste. <b>Note:</b> Most effective when taken on an empty stomach.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation: Nebulization: Mix injectable solution with albuterol ± ipratropium and administer over 15 to 20 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24429155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24429155'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Infants and Children: Dilute prior to injection; in adults, doses are administered undiluted (50%) or diluted in a compatible fluid.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Dilute in an appropriate fluid prior to administration. Rate of infusion dependent upon use:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hypomagnesemia: </i>
<b>Note: </b>Rate should be slowed if patient experiences diaphoresis, flushing, or a warm sensation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Asymptomatic: In asymptomatic patients, a rate of ≤0.1 mEq/kg/hour of <b>elemental magnesium</b> (~12.5 mg/kg/hour <b>magnesium sulfate</b>) may be considered (in adults, the usual rate is ≤1,000 mg/hour of <b>magnesium sulfate</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Urgent/emergent: Infuse slowly over 15 to 20 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pulseless ventricular tachycardia (VT) associated with torsades:</i> May administer as a bolus over several minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>VT with pulses associated with torsades:</i> Infuse over 10 to 20 minutes; rapid infusion may cause hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Asthma exacerbation (severe):</i> Infuse over 15 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-GINA.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-GINA.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: After dilution, administer via an infusion pump.</p></div>
<div class="block adm drugH1Div" id="F191070"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> May be administered IM, intraosseous (IO), or IV.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Adults: 50% concentration.</p>
<p style="text-indent:-2em;margin-left:6em;">Eclampsia/preeclampsia: May mix with lidocaine 2% to reduce injection pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV, intraosseous: Must be diluted to a ≤20% solution for IV infusion and may be administered IVP, IVPB, as a continuous IV infusion, or IO. When giving IV push, must dilute first and should generally not be given any faster than 150 mg/minute. In patients not in cardiac arrest, hypotension and asystole may occur with rapid administration. Refer to indication-specific infusion rates in dosing for detailed recommendations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> When used as a laxative, dissolve dose in 8 ounces of water prior to ingesting. Lemon juice may be added to the solution to improve the taste.</p></div>
<div class="block sts drugH1Div" id="F191080"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Prior to use, store at room temperature of 20°C to 25°C (68°F to 77°F). Do not freeze. Refrigeration of solution may result in precipitation or crystallization.</p></div>
<div class="block usep drugH1Div" id="F53567655"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Laxative for the relief of occasional constipation (OTC product: FDA approved in ages ≥6 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment and prevention of hypomagnesemia (FDA approved in all ages); prevention and treatment of seizures in severe preeclampsia or eclampsia (FDA approved in pregnant females); has also been used intravenously and via oral nebulization for adjunctive treatment of asthma exacerbation (severe, life-threatening) unresponsive to 1 hour of intensive conventional treatment and intravenously for treatment of torsade de pointes or ventricular fibrillation/pulseless ventricular tachycardia associated with torsade de pointes.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical: Soaking aid for minor sprains and bruises (OTC product: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F191104"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Magnesium sulfate may be confused with manganese sulfate, morphine sulfate </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">MgSO<sub>4</sub> is an error-prone abbreviation (mistaken as morphine sulfate) </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299640"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F191059"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving alfacalcidol.  If magnesium-containing products must be used with alfacalcidol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts.  Management: Separate administration of alpha-lipoic acid from that of any magnesium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral magnesium-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir.  Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Dihydropyridine): Magnesium Sulfate may enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: Magnesium Sulfate may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after use of a magnesium-containing antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Magnesium Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar/enox-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe/enox-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May enhance the adverse/toxic effect of Magnesium Sulfate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.  Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F4104770"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Increased alcohol intake can deplete magnesium stores (IOM, 1997).</p></div>
<div class="block dic drugH1Div" id="F191076"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Whole grains, legumes and dark-green leafy vegetables are dietary sources of magnesium (IOM 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adequate intake (AI) (elemental magnesium) (IOM 1997):</b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 6 months: 30 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: 75 mg daily</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary recommended daily allowance (RDA) (elemental magnesium) (IOM 1997):</b></p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: 80 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: 130 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: 240 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 360 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 400 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 360 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 410 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 30 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 310 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 350 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 310 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 400 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">≥31 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 320 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 360 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 320 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 420 mg daily</p></div>
<div class="block pri drugH1Div" id="F3013521"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama 1998; Osada 2002). Continuous maternal use for &gt;5 to 7 days (in doses such as those used for preterm labor, an off-label use) may cause fetal hypocalcemia and bone abnormalities, as well as fractures in the neonate.</p>
<p style="text-indent:0em;margin-top:2em;">Magnesium sulfate injection is used for the prevention and treatment of seizures in pregnant or postpartum patients with eclampsia or preeclampsia with severe features. The risk of morbidity and mortality is increased in preeclampsia with severe features (ACOG 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Magnesium sulfate may also be used prior to early preterm delivery for neuroprotection to reduce the risk of cerebral palsy (ACOG 2010; Reeves 2011); treatment may be of benefit when birth is anticipated before 32 weeks' gestation (ACOG 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth; maintenance therapy with tocolytics is ineffective and not recommended. Magnesium sulfate can be used up to 48 hours in patients at risk of delivery within 7 days; however, it is not the preferred tocolytic (ACOG 2016). Magnesium sulfate injection may be used in conjunction with other tocolytics for neuroprotection; however, an increased risk of maternal complications may be observed when used in combination with some tocolytic agents (ACOG 2016).</p></div>
<div class="block mopp drugH1Div" id="F53567638"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Stool output (laxative use).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Rapid administration: ECG monitoring, vital signs, deep tendon reflexes; magnesium concentrations if frequent or prolonged dosing required particularly in patients with renal dysfunction, calcium, and potassium concentrations; renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">Obstetrics: Patient status including vital signs, oxygen saturation, deep tendon reflexes, level of consciousness, fetal heart rate, maternal uterine activity.</p></div>
<div class="block rerp drugH1Div" id="F53567528"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Typical values: Total magnesium: 1.5 to 2.5 mEq/L.</p></div>
<div class="block pha drugH1Div" id="F191053"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">When taken orally, magnesium promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity; parenterally, magnesium decreases acetylcholine in motor nerve terminals and acts on myocardium by slowing rate of S-A node impulse formation and prolonging conduction time. Magnesium is necessary for the movement of calcium, sodium, and potassium in and out of cells, as well as stabilizing excitable membranes.</p>
<p style="text-indent:0em;margin-top:2em;">Intravenous magnesium may improve pulmonary function in patients with asthma; causes relaxation of bronchial smooth muscle independent of serum magnesium concentration.</p></div>
<div class="block phk drugH1Div" id="F191072"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Antiseizure medication: IM: 1 hour; IV: Immediate; Laxative: Oral: 0.5 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of antiseizure activity: IM: 3 to 4 hours; IV: 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Slow and poor (approximately one-third absorbed)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Bone (50% to 60%); extracellular fluid (1% to 2%) (IOM 1997)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 30%, to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as magnesium); feces (as unabsorbed drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4088911"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Sulfato de magnesio | Sulfato de magnesio apolo</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cormagnesin | Magnesium sulfur</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Epsom | Magnesium sulphate</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Nalepsin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulfate sterop</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cormagnesin | Magnesium sulfuricum</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hypomagne | Magnoston | Sulfato de magnesio</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Sulfato de magnesio | Sulfato magnesia | Sulfato magnesio</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulfuric</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lasar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sulfato de magnesio genfarma</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Addex-magnesium | Mg-konsentraatti</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Spasmag | Sulfate de magnesium lavoisier</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mag sulphate | Magnesium sulphate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cormagnesin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulphate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulphate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Magneon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Magnesio solfato</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Conclyte mg mitsubishi | Conclyte mg otsuka</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Nalepsin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulphate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Magnesii sulfas | Magnesium Sulfat | Magnesium sulfuric</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulfuric</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Spasmag</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ifupeptol magnesiado | Sulfato de magnesio</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Addex-magnesium | Magnesiumsulfat</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulphate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Sulfagnesium</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hizon magnesium sulfate</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulphate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Magnesio solfato monico</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Magnesio sulfato catedral</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cormagnesin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulfate j | Magnesium sulfuric | Magnesium sulfuricum</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Addex-magnesium | Magnesio Solfato S.A.L.F.</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulphate | Magnesium Sulphate hospira</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulfuricum</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Multiflex magnezyum sulfat | Pre eklamol magnezyum sulfat | Turktipsan magnezyum sulfat</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Magnesium sulfuric</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sulfato de magnesio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12057549">
<a name="12057549"></a>Altman D, Carroli G, Duley L, et al; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. <i>Lancet</i>. 2002;359(9321):1877-1890. doi:10.1016/s0140-6736(02)08778-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/12057549/pubmed" id="12057549" target="_blank">12057549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CFR201.1">
<a name="CFR201.1"></a>Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20177305">
<a name="20177305"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. <i>Obstet Gynecol.</i> 2010;115(3):669-671. doi: 10.1097/AOG.0b013e3181d4ffa5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20177305/pubmed" id="20177305" target="_blank">20177305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27661654">
<a name="27661654"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 171: Management of preterm labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi:10.1097/AOG.0000000000001711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/27661654/pubmed" id="27661654" target="_blank">27661654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443079">
<a name="32443079"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 222: Gestational hypertension and preeclampsia. <i>Obstet Gynecol</i>. 2020;135(6):e237-e260. doi:10.1097/AOG.0000000000003891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/32443079/pubmed" id="32443079" target="_blank">32443079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.1">
<a name="ASPEN.1"></a>American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition. http://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-FINAL.pdf. Published January 8, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24100128">
<a name="24100128"></a>Ayuk J, Gittoes NJ. Treatment of hypomagnesemia. <i>Am J Kidney Dis</i>. 2014;63(4):691-695. doi:10.1053/j.ajkd.2013.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/24100128/pubmed" id="24100128" target="_blank">24100128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2385256">
<a name="2385256"></a>Bashuk RG, Krendel DA. Myasthenia gravis presenting as weakness after magnesium administration. <i>Muscle Nerve</i>. 1990;13(8):708-712. doi:10.1002/mus.880130808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/2385256/pubmed" id="2385256" target="_blank">2385256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30259065">
<a name="30259065"></a>Becker SM, Job KM, Lima K, et al. Prospective study of serum and ionized magnesium pharmacokinetics in the treatment of children with severe acute asthma. <i>Eur J Clin Pharmacol</i>. 2019;75(1):59‐66. doi:10.1007/s00228-018-2557-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/30259065/pubmed" id="30259065" target="_blank">30259065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berul.1">
<a name="Berul.1"></a>Berul CI. Acquired long QT syndrome: clinical manifestations, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16235345">
<a name="16235345"></a>Blitz M, Blitz S, Beasely R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. <i>Cochrane Database Syst Rev</i>. 2005;19(4):CD003898. doi:10.1002/14651858.CD003898.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/16235345/pubmed" id="16235345" target="_blank">16235345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7781349">
<a name="7781349"></a>Bloch H, Silverman R, Mancherje N, et al. Intravenous Magnesium Sulfate as an Adjunct in the Treatment of Acute Asthma. <i>Chest.</i> 1995;107(6):1576-1581. doi: 10.1378/chest.107.6.1576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7781349/pubmed" id="7781349" target="_blank">7781349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2120648">
<a name="2120648"></a>Bohman VR, Cotton DB. Supralethal magnesemia with patient survival. <i>Obstet Gynecol</i>. 1990;76(5, pt 2):984-986.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/2120648/pubmed" id="2120648" target="_blank">2120648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6504426">
<a name="6504426"></a>Catanzarite VA, McHargue AM, Sandberg EC, Dyson DC. Respiratory arrest during therapy for premature labor in a patient with myasthenia gravis. <i>Obstet Gynecol</i>. 1984;64(6):819-822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/6504426/pubmed" id="6504426" target="_blank">6504426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7037303">
<a name="7037303"></a>Chernow B, Smith J, Rainey TG, Finton C. Hypomagnesemia: implications for the critical care specialist. <i>Crit Care Med</i>. 1982;10(3):193-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7037303/pubmed" id="7037303" target="_blank">7037303</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cheuk DK, Chau TC, Lee SL. A Meta-analysis on Intravenous Magnesium Sulphate for Treating Acute Asthma. <i>Arch Dis Child</i>. 2005;90(1):74-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/15613519 /pubmed" id="15613519 " target="_blank">15613519 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11030848">
<a name="11030848"></a>Ciarallo L, Brousseau D, Reinert S. Higher-Dose Intravenous Magnesium Therapy for Children With Moderate to Severe Acute Asthma. <i>Arch Pediatr Adolesc Med</i>. 2000;154(10):979-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/11030848/pubmed" id="11030848" target="_blank">11030848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8969721">
<a name="8969721"></a>Ciarallo L, Sauer AH, Shannon MW. Intravenous Magnesium Therapy for Moderate to Severe Pediatric Asthma: Results of a Randomized, Placebo-Controlled Trial. <i>J Pediatr</i>. 1996;129(6):809-814. doi:10.1016/s0022-3476(96)70023-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/8969721/pubmed" id="8969721" target="_blank">8969721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-940634">
<a name="940634"></a>Cohen BA, London RS, Goldstein PJ. Myasthenia gravis and preeclampsia. <i>Obstet Gynecol</i>. 1976;48(1)(suppl):35S-37S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/940634/pubmed" id="940634" target="_blank">940634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkins.1">
<a name="Corkins.1"></a>Corkins MR, Balint J, Corkins KG, Bobo E, Plogsted S, Yaworski, JA, eds. <i>A.S.P.E.N. Pediatric Nutrition Support Handbook</i>. 2nd ed. American Society for Enteral and Parenteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23616673">
<a name="23616673"></a>Couture J, Létourneau A, Dubuc A, Williamson D. Evaluation of an electrolyte repletion protocol for cardiac surgery intensive care patients. <i>Can J Hosp Pharm</i>. 2013;66(2):96-103. doi:10.4212/cjhp.v66i2.1231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/23616673/pubmed" id="23616673" target="_blank">23616673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14645308">
<a name="14645308"></a>Crowther CA, Hiller JE, Doyle LW, Haslam RR; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. <i>JAMA</i>. 2003;290(20):2669-2676. doi:10.1001/jama.290.20.2669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/14645308/pubmed" id="14645308" target="_blank">14645308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7091241">
<a name="7091241"></a>Cruikshank DP, Varner MW, Pitkin RM. Breast milk magnesium and calcium concentrations following magnesium sulfate treatment. <i>Am J Obstet Gynecol</i>. 1982;143(6):685-688. doi:10.1016/0002-9378(82)90115-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7091241/pubmed" id="7091241" target="_blank">7091241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26069820">
<a name="26069820"></a>Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. <i>Clin Kidney J.</i> 2012;5(suppl 1):i39-i51. doi:10.1093/ndtplus/sfr166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/26069820/pubmed" id="26069820" target="_blank">26069820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17125434">
<a name="17125434"></a>Dager WE, Sanoski CA, Wiggins BS, Tisdale JE. Pharmacotherapy considerations in advanced cardiac life support. <i>Pharmacotherapy</i>. 2006;26(12):1703-1729. doi:10.1592/phco.26.12.1703<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/17125434/pubmed" id="17125434" target="_blank">17125434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26629718">
<a name="26629718"></a>De Silva DA, Sawchuck D, von Dadelszen P, et al. Magnesium sulphate for eclampsia and fetal neuroprotection: a comparative analysis of protocols across Canadian tertiary perinatal centres. <i>J Obstet Gynaecol Can</i>. 2015;37(11):975-987. doi:10.1016/s1701-2163(16)30047-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/26629718/pubmed" id="26629718" target="_blank">26629718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10763902">
<a name="10763902"></a>Dórea JG. Magnesium in human milk. <i>J Am Coll Nutr</i>. 2000;19(2):210-219. doi:10.1080/07315724.2000.10718919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/10763902/pubmed" id="10763902" target="_blank">10763902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12944451">
<a name="12944451"></a>Dubé L, Granry JC. The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: a review. <i>Can J Anaesth</i>. 2003;50(7):732-746. doi:10.1007/BF03018719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/12944451/pubmed" id="12944451" target="_blank">12944451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20687086">
<a name="20687086"></a>Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. <i>Cochrane Database Syst Rev</i>. 2010;(8):CD007388. doi:10.1002/14651858.CD007388.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20687086/pubmed" id="20687086" target="_blank">20687086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7769899">
<a name="7769899"></a>Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. <i>Lancet</i>. 1995;345(8963):1455-1463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7769899/pubmed" id="7769899" target="_blank">7769899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epsom.1">
<a name="Epsom.1"></a>Epsom salt (magnesium sulfate) [prescribing information]. Portland, OR: Western Family Foods Inc; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epsom.2">
<a name="Epsom.2"></a>Epsom salt (magnesium sulfate) [prescribing information]. Woonsocket, RI: CVS Pharmacy, Inc; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epsom.3">
<a name="Epsom.3"></a>Epsom salt (magnesium sulfate) [prescribing information]. Deerfield, IL: Walgreen Co; received September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S640-S656. doi:10.1161/CIRCULATIONAHA.110.970889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferroggiaro.1">
<a name="Ferroggiaro.1"></a>Ferroggiaro A, Walther JM, Cairns CB. High doses of magnesium impair cardiac oxidative metabolism. <i>Acad Emerg Med.</i> 1995;2:423-429.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2020">
<a name="GINA.2020"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Updated 2020. Accessed May 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26078288">
<a name="26078288"></a>Guenter P, Boullata JI, Ayers P, et al; Parenteral Nutrition Safety Task Force, American Society for Parenteral and Enteral Nutrition (ASPEN). Standardized competencies for parenteral nutrition prescribing: the American Society for Parenteral and Enteral Nutrition model. <i>Nutr Clin Pract</i>. 2015;30(4):570-576. doi:10.1177/0884533615591167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/26078288/pubmed" id="26078288" target="_blank">26078288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621856">
<a name="19621856"></a>Guerrera MP, Volpe SL, Mao JJ. Therapeutic uses of magnesium. <i>Am Fam Physician</i>. 2009;80(2):157-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/19621856/pubmed" id="19621856" target="_blank">19621856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3552543">
<a name="3552543"></a>Gums JG. Clinical significance of magnesium: a review. <i>Drug Intell Clin Pharm</i>. 1987;21(3):240-246. doi:10.1177/106002808702100301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/3552543/pubmed" id="3552543" target="_blank">3552543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15372830">
<a name="15372830"></a>Gums JG. Magnesium in cardiovascular and other disorders. <i>Am J Health Syst Pharm</i>. 2004;61(15):1569-1576. doi:10.1093/ajhp/61.15.1569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/15372830/pubmed" id="15372830" target="_blank">15372830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32498528">
<a name="32498528"></a>Han Z, Zhou L, Liu R, Feng L. The effect of hemodialysis on serum magnesium concentration in hemodialysis patients. <i>Ann Palliat Med.</i> 2020;9(3):1134-1143. doi:10.21037/apm-20-992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/32498528/pubmed" id="32498528" target="_blank">32498528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hazinski.1">
<a name="Hazinski.1"></a>Hazinski MF, Shuster M, Donnino MW, et al.<i> 2015 Handbook of Emergency Cardiovascular Care for Healthcare Providers</i>. American Heart Association; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9532984">
<a name="9532984"></a>Idama TO, Lindow SW. Magnesium sulphate: a review of clinical pharmacology applied to obstetrics. <i>Br J Obstet Gynaecol</i>. 1998;105(3):260-268. doi:10.1111/j.1471-0528.1998.tb10084.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/9532984/pubmed" id="9532984" target="_blank">9532984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP). Preventing Magnesium Toxicity in Obstetrics. <i>ISMP Acute Care Medication Safety Alert.</i> October 20, 2005. https://www.ismp.org/resources/preventing-magnesium-toxicity-obstetrics.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride.</i> National Academy of Sciences; 1997.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35099052">
<a name="35099052"></a>Jahangir A, Zia Z, Niazi MRK, et al. Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. <i>Adv Respir Med</i>. Published online January 31, 2022. doi:10.5603/ARM.a2022.0012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/35099052/pubmed" id="35099052" target="_blank">35099052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6148832">
<a name="6148832"></a>Kaeser HE. Drug-induced myasthenic syndromes. <i>Acta Neurol Scand Suppl</i>. 1984;100:39-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/6148832/pubmed" id="6148832" target="_blank">6148832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010 Nov 2;122(18)(suppl 3):S876-S908. doi:10.1161/CIRCULATIONAHA.110.971101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16085929">
<a name="16085929"></a>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005;62(16):1663-1682. doi:10.2146/ajhp040300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/16085929/pubmed" id="16085929" target="_blank">16085929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14523145">
<a name="14523145"></a>Lembo A, Camilleri M. Chronic constipation. <i>N Engl J Med</i>. 2003;349(14):1360-1368. doi:10.1056/NEJMra020995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/14523145/pubmed" id="14523145" target="_blank">14523145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27885772">
<a name="27885772"></a>Long Q, Oladapo OT, Leathersich S, et al; WHO Multicountry Survey on Maternal and Newborn Health Research Network. Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey. <i>BJOG</i>. 2017;124(12):1883-1890. doi:10.1111/1471-0528.14400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/27885772/pubmed" id="27885772" target="_blank">27885772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7791836">
<a name="7791836"></a>Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia.<i> N Engl J Med</i>. 1995;333(4):201-205 .doi:10.1056/NEJM199507273330401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7791836/pubmed" id="7791836" target="_blank">7791836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Magnesium.1">
<a name="Magnesium.1"></a>Magnesium sulfate injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Magnesium.2">
<a name="Magnesium.2"></a>Magnesium sulfate in dextrose (5%) [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Magnesium.3">
<a name="Magnesium.3"></a>Magnesium sulfate in water for injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Magnesium.4">
<a name="Magnesium.4"></a>Magnesium sulfate in water injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Magnesium.5">
<a name="Magnesium.5"></a>Magnesium sulfate in water for injection with flexible plastic container [prescribing information]. Lake Zurich, IL: Hospira Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17169012">
<a name="17169012"></a>Marret S, Marpeau L, Zupan-Simunek V, et al; PREMAG trial group. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. <i>BJOG</i>. 2007;114(3):310-318. doi:10.1111/j.1471-0528.2006.01162.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/17169012/pubmed" id="17169012" target="_blank">17169012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568296">
<a name="15568296"></a>Mirtallo J, Canada T, Johnson D, et al; Task Force for the Revision of Safe Practices for Parenteral Nutrition. Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70. doi:10.1177/0148607104028006s39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/15568296/pubmed" id="15568296" target="_blank">15568296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18029512">
<a name="18029512"></a>Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. <i>Emerg Med J</i>. 2007;24(12):823-830. doi:10.1136/emj.2007.052050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/18029512/pubmed" id="18029512" target="_blank">18029512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26905985">
<a name="26905985"></a>Mukerji S, Shahpuri B, Clayton-Smith B, et al. Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. <i>N Z Med J</i>. 2015;128(1425):34-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/26905985/pubmed" id="26905985" target="_blank">26905985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17983880">
<a name="17983880"></a>National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. <i>J Allergy Clin Immunol</i>. 2007;120(5)(suppl):S94-S138. doi:10.1016/j.jaci.2007.09.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/17983880/pubmed" id="17983880" target="_blank">17983880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35616126">
<a name="35616126"></a>Ni H, Aye SZ, Naing C. Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease. <i>Cochrane Database Syst Rev</i>. 2022;5(5):CD013506. doi:10.1002/14651858.CD013506.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/35616126/pubmed" id="35616126" target="_blank">35616126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norwitz.1">
<a name="Norwitz.1"></a>Norwitz ER. Eclampsia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norwitz.2">
<a name="Norwitz.2"></a>Norwitz ER. Preeclampsia: intrapartum and postpartum managementand long-term prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12366483">
<a name="12366483"></a>Osada H, Watanabe Y, Nishimura Y, Yukawa M, Seki K, Sekiya S. Profile of trace element concentrations in the feto-placental unit in relation to fetal growth. <i>Acta Obstet Gynecol Scand</i>. 2002;81(10):931-937. doi:10.1034/j.1600-0412.2002.811006.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/12366483/pubmed" id="12366483" target="_blank">12366483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17686630">
<a name="17686630"></a>Owen P, Monahan MF, MacLaren R. Implementing and assessing an evidence-based electrolyte dosing order form in the medical ICU. <i>Intensive Crit Care Nurs</i>. 2008;24(1):8-19. doi:10.1016/j.iccn.2007.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/17686630/pubmed" id="17686630" target="_blank">17686630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30571262">
<a name="30571262"></a>Panchal AR, Berg KM, Kudenchuk PJ, et al. 2018 American Heart Association focused update on advanced cardiovascular life support use of antiarrhythmic drugs during and immediately after cardiac arrest: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2018;138(23):e740-e749. doi:10.1161/CIR.0000000000000613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/30571262/pubmed" id="30571262" target="_blank">30571262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429155">
<a name="24429155"></a>Powell C, Kolamunnage-Dona R, Lowe J, et al. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. <i>Lancet Respir Med</i>. 2013;1(4):301-308. doi:10.1016/S2213-2600(13)70037-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/24429155/pubmed" id="24429155" target="_blank">24429155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pozner.1">
<a name="Pozner.1"></a>Pozner CN, Walls RM. Advanced cardiac life support (ACLS) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26485229">
<a name="26485229"></a>Pratt JJ, Niedle PS, Vogel JP, et al. Alternative regimens of magnesium sulfate for treatment of preeclampsia and eclampsia: a systematic review of non-randomized studies. <i>Acta Obstet Gynecol Scand</i>. 2016;95(2):144-156. doi:10.1111/aogs.12807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/26485229/pubmed" id="26485229" target="_blank">26485229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21376159">
<a name="21376159"></a>Reeves SA, Gibbs RS, Clark SL. Magnesium for fetal neuroprotection. <i>Am J Obstet Gynecol</i>. 2011;204(3):202.e1-e4. doi:10.1016/j.ajog.2011.01.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/21376159/pubmed" id="21376159" target="_blank">21376159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27909740">
<a name="27909740"></a>Rower JE, Liu X, Yu T, Mundorff M, Sherwin CM, Johnson MD. Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma. <i>Eur J Clin Pharmacol</i>. 2017;73(3):325‐331. doi:10.1007/s00228-016-2165-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/27909740/pubmed" id="27909740" target="_blank">27909740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11097697">
<a name="11097697"></a>Scarfone RJ, Loiselle JM, Joffe MD, et al. A Randomized Trial of Magnesium in the Emergency Department Treatment of Children With Asthma. <i>Ann Emerg Med</i>. 2000;36(6):572-578. doi:10.1067/mem.2000.111060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/11097697/pubmed" id="11097697" target="_blank">11097697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simhan.1">
<a name="Simhan.1"></a>Simhan HN, Himes KP. Neuroprotective effects of in utero exposure to magnesium sulfate. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Siparsky.1">
<a name="Siparsky.1"></a>Siparsky N. Overview of postoperative electrolyte abnormalities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7864705">
<a name="7864705"></a>Skorodin MS, Tenholder MF, Yetter B, et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. <i>Arch Intern Med</i>. 1995;155(5):496-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/7864705/pubmed" id="7864705" target="_blank">7864705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19969151">
<a name="19969151"></a>Todd SR, Sucher JF, Moore LJ, Turner KL, Hall JB, Moore FA. A multidisciplinary protocol improves electrolyte replacement and its effectiveness. <i>Am J Surg</i>. 2009;198(6):911-915. doi:10.1016/j.amjsurg.2009.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/19969151/pubmed" id="19969151" target="_blank">19969151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32542879">
<a name="32542879"></a>Vafadar Moradi E, Pishbin E, Habibzadeh SR, Talebi Doluee M, Soltanifar A. The adjunctive effect of intravenous magnesium sulfate in acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled clinical trial. <i>Acad Emerg Med</i>. 2021;28(3):359-362. doi:10.1111/acem.14050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/32542879/pubmed" id="32542879" target="_blank">32542879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vissers.1">
<a name="Vissers.1"></a>Vissers R, Purssell R. Iatrogenic intravenous magnesium overdose causing cardiac arrest. <i>J Toxicol Clin Toxicol.</i> 1995;33(5):489.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4447250">
<a name="4447250"></a>Worthley LI. Lithium toxicity and refractory cardiac arrhythmia treated with intravenous magnesium. <i>Anaesth Intensive Care</i>. 1974;2(4):357-360. doi: 10.1177/0310057X7400200411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/4447250/pubmed" id="4447250" target="_blank">4447250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yu.1">
<a name="Yu.1"></a>Yu ASL. Hypomagnesemia: evaluation and treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27391902">
<a name="27391902"></a>Zakharchenko M, Los F, Brodska H, Balik M. The effects of high level magnesium dialysis/substitution fluid on magnesium homeostasis under regional citrate anticoagulation in critically ill. <i>PLoS One</i>. 2016;11(7):e0158179. doi:10.1371/journal.pone.0158179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/magnesium-sulfate-pediatric-drug-information/abstract-text/27391902/pubmed" id="27391902" target="_blank">27391902</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12982 Version 482.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
